{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:04:21Z","timestamp":1792242261150,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T00:00:00Z","timestamp":1411689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HZ cases were identified as those reported by trial investigators from the databases of the phase II, phase III, and long\u2010term extension (LTE) clinical trials in the Tofacitinib RA Development Program. Crude incidence rates (IRs) of HZ per 100 patient\u2010years (with 95% confidence intervals [95% CIs]) were calculated by exposure group. Logistic regression analyses were performed to evaluate potential risk factors for HZ (e.g., age, prednisone use).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 4,789 participants, 239 were identified as having tofacitinib\u2010associated HZ during the phase II, phase III, and LTE trials, of whom 208 (87%) were female and whose median age was 57 years (range 21\u201375 years). One HZ case (0.4%) was multidermatomal; none of the cases involved visceral dissemination or death. Twenty\u2010four patients with HZ (10%) permanently discontinued treatment with tofacitinib, and 16 (7%) were either hospitalized or received intravenous antiviral drugs. The crude HZ IR across the development program was 4.4 per 100 patient\u2010years (95% CI 3.8\u20134.9), but the IR was substantially higher within Asia (7.7 per 100 patient\u2010years, 95% CI 6.4\u20139.3). Older age was associated with HZ (odds ratio 1.9, 95% CI 1.5\u20132.6), and IRs for HZ were similar between patients receiving 5 mg tofacitinib twice daily (4.4 per 100 patient\u2010years, 95% CI 3.2\u20136.0) and those receiving 10 mg twice daily (4.2 per 100 patient\u2010years, 95% CI 3.1\u20135.8). In the phase III trials among placebo recipients, the incidence of HZ was 1.5 per 100 patient\u2010years (95% CI 0.5\u20134.6).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the Tofacitinib RA Development Program, increased rates of HZ were observed in patients treated with tofacitinib compared with those receiving placebo, particularly among patients within Asia. Complicated HZ among tofacitinib\u2010treated patients was rare.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.38745","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T14:06:48Z","timestamp":1403100408000},"page":"2675-2684","source":"Crossref","is-referenced-by-count":308,"title":["Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis"],"prefix":"10.1002","volume":"66","author":[{"given":"Kevin L.","family":"Winthrop","sequence":"first","affiliation":[{"name":"Oregon Health &amp; Science University Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Tokyo Women's Medical University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chew","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Krishnaswami","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Riese","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,26]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz R","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200211000-00002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318065b6c9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.67"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133843"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1099"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"issue":"10","key":"e_1_2_8_12_1","first-page":"S854","article-title":"Tofacitinib (CP\u2010690,550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12\u2010week phase IIb study","volume":"63","author":"Tanaka Y","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_2_8_14_1","unstructured":"TanakaY YamanakaH NakamuraH TakeuchiT. Study results of oral JAK inhibitor tofacitinib in patients with active RA [abstract]. Presented at the 55th Annual Scientific Meeting of the Japan College of Rheumatology Kobe Japan July 17\u201320 2011. URL:http:\/\/www.jcr2011.com."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202442"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"issue":"10","key":"e_1_2_8_23_1","first-page":"S473","article-title":"Tofacitinib (CP,690,550), an oral Janus kinase inhibitor, as monotherapy or with background methotrexate in Japanese patients with rheumatoid arthritis: a phase 2\/3 long\u2010term extension study","volume":"63","author":"Yamanaka H","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/598331"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90568-I"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125658"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21568"},{"key":"e_1_2_8_30_1","unstructured":"US Food and Drug Administration. Drug approval package Actemra (tocilizumab) injection: medical review Table 4 and Table 6;2010. URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125276s000MedR.pdf."},{"key":"e_1_2_8_31_1","unstructured":"US Food and Drug Administration. Arthritis Advisory Committee meeting to discuss BLA 125276 for tocilizumab for the treatment of moderately to severely active rheumatoid arthritis (RA);2008. URL:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008\u20104371b1\u201001\u2010FDA.pdf."},{"key":"e_1_2_8_32_1","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten AL","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.32.1.24-27.1981"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1086\/379048"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1086\/592219"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/528696"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/1079990041689665"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000177643.05739.cd"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10315"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151092"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21599"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3497"},{"key":"e_1_2_8_44_1","unstructured":"American College of Rheumatology. Update on herpes zoster (shingles) vaccine for autoimmune disease patients;2013. URL:http:\/\/www.rheumatology.org\/publications\/hotline\/2012_09_12_herpeszoster.asp."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38745","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38745","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.38745","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:36:26Z","timestamp":1759937786000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,26]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1002\/art.38745"],"URL":"https:\/\/doi.org\/10.1002\/art.38745","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,26]]}}}